ABPO at a glance
The past year
Chart−90.3% $0.53, close Nov 16
- From the highest close
- −92.5%
- Vs the 200-day average
- +69.5%
Short interest
History15,840 shares
- Since the last report
- −1.6%
- Days to cover
- 1.0 day
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 12 – Nov 18
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
ABPO price history
Loading recent earnings…
Investment thesis
What must happen next
Celltrion’s continued commitment is the critical external validation mechanism for ABP-102, because Abpro’s platform economics depend on partner-funded milestones rather than recurring commercial sales.HoldingMateriality: High
Item 1 Business states ABP-102 is being developed and commercialized through a worldwide strategic partnership with Celltrion. If Celltrion remains engaged, ABPO has a credible path to non-dilutive value creation; if Celltrion steps back, the platform loses its most important validation and funding channel.
Watch: Celltrion terminates, materially narrows, or stops funding the ABP-102 collaboration.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 Business states ABP-102 is being developed and commercialized through a worldwide strategic partnership with Celltrion.
Open source ↗Abpro must secure outside capital or partner cash before the pipeline can create value, because liquidity—not market demand for an approved product—is the immediate gating constraint.WeakeningMateriality: High
FY2025 cash was only $82,000 at year-end. If financing arrives on acceptable terms, shareholders retain exposure to ABP-102; if it does not, dilution, restructuring, or insolvency can erase the option value.
Watch: Nasdaq denies the delisting appeal, further limiting access to institutional capital.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 cash was only $82,000 at year-end.
Open source ↗Management must keep the operating model lean enough for partner milestones or financings to bridge the company to clinical data; a clinical-spend ramp without new funding would overwhelm the balance sheet.HoldingMateriality: Medium
GAAP annual operating cash flow improved to negative $6.006 million in FY2025 from negative $9.030 million in FY2024. Burn discipline extends the life of the ABP-102 option; loss of discipline forces distressed financing before any scientific proof point can re-rate the company.
Watch: ABP-102 clinical trial initiation materially increases CRO, manufacturing, and regulatory cash needs before financing is secured.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow improved to negative $6.006 million in FY2025 from negative $9.030 million in FY2024.
Open source ↗The OTC Pink trading status and negative equity position make capital access a central operating risk, so per-share value depends on restoring market credibility or finding strategic capital outside the public market.WeakeningMateriality: Medium
Item 1 Business states Abpro was delisted from Nasdaq effective February 23, 2026 and currently trades on the OTC Pink Limited Market. A relisting or strategic financing could preserve upside for common holders; continued capital-market impairment shifts value toward creditors and new money.
Watch: Nasdaq denies the company’s appeal of the delisting determination.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 Business states Abpro was delisted from Nasdaq effective February 23, 2026 and currently trades on the OTC Pink.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Celltrion’s continued commitment is the critical external validation mechanism for ABP-102, because Abpro’s platform economics depend on partner-funded milestones rather than recurring commercial sales. If Celltrion remains engaged, ABPO has a credible path to non-dilutive value creation; if Celltrion steps back, the platform loses its most important validation and funding channel.
Abpro must secure outside capital or partner cash before the pipeline can create value, because liquidity—not market demand for an approved product—is the immediate gating constraint. If financing arrives on acceptable terms, shareholders retain exposure to ABP-102; if it does not, dilution, restructuring, or insolvency can erase the option value.
Management must keep the operating model lean enough for partner milestones or financings to bridge the company to clinical data; a clinical-spend ramp without new funding would overwhelm the balance sheet. Burn discipline extends the life of the ABP-102 option; loss of discipline forces distressed financing before any scientific proof point can re-rate the company.
The OTC Pink trading status and negative equity position make capital access a central operating risk, so per-share value depends on restoring market credibility or finding strategic capital outside the public market. A relisting or strategic financing could preserve upside for common holders; continued capital-market impairment shifts value toward creditors and new money.
All standing thesis claims
Original report summary
ABPO is a distressed biotech call option on whether its TetraBi antibody platform, led by ABP-102 and backed by Celltrion, can reach clinical validation before financing risk overwhelms common shareholders.
Bull case and bear case
Bull case and bear case for Abpro Holdings
Where the evidence on Abpro Holdings disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 4 thesis points, 2 holding and 2 weakening.
Bull case: what the evidence supports
Celltrion’s continued commitment is the critical external validation mechanism for ABP-102, because Abpro’s platform economics depend on partner-funded milestones rather than recurring commercial sales.
Management must keep the operating model lean enough for partner milestones or financings to bridge the company to clinical data; a clinical-spend ramp without new funding would overwhelm the balance sheet.
Bear case: what the evidence questions
Abpro must secure outside capital or partner cash before the pipeline can create value, because liquidity—not market demand for an approved product—is the immediate gating constraint.
The OTC Pink trading status and negative equity position make capital access a central operating risk, so per-share value depends on restoring market credibility or finding strategic capital outside the public market.
Thesis-Break Engine
What has broken in Abpro Holdings’s thesis
Each break OptimistFi flagged on Abpro Holdings, dated — with what has historically followed the same kind of break across the market, not a forecast for Abpro Holdings.
- Late SEC filingcondition set before this filing
Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDirector or principal officer change.
Abpro Holdings filed an SEC 8-K on 2026-09-01: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Abpro Holdings filed an SEC 8-K on 2026-08-25: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedDelisting notice or listing-rule failure.
Abpro Holdings filed an SEC 8-K on 2026-06-04: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Celltrion terminates, materially narrows, or stops funding the ABP-102 collaboration.
- Nasdaq denies the delisting appeal, further limiting access to institutional capital.
- ABP-102 clinical trial initiation materially increases CRO, manufacturing, and regulatory cash needs before financing is secured.
- Nasdaq denies the company’s appeal of the delisting determination.
ABPO news
Loading headlines…
Financial statements
ABPO income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ABPO: quick answers
- What is ABPO's short interest?
- As of October 30, 2026, 15,840 ABPO shares were sold short, down 1.6% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. ABPO short interest history

